Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
27 oct. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
19 oct. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
12 oct. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
05 oct. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
28 sept. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
11 août 2022 08h05 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
12 mai 2022 08h00 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE...
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
24 mars 2022 08h00 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling 3rd Dose-Level Cohort ...
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
08 mars 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Clinical and Preclinical Program Updates
15 févr. 2022 08h05 HE
|
Monopar Therapeutics Inc.
Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15,...